TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25677851
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group (detectable TnT ≥0.01 ng/mL and BNP >440 pg/mL)
Study: 25679067
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + nP + T (gemcitabine + nab-paclitaxel + TH-302)
Study: 25679067
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + nP (gemcitabine + nab-paclitaxel)
Study: 25679107
Drug: Early peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early peripheral perfusion-guided fluid therapy
Study: 25679125
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment for 6 months
Study: 25680594
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) plus cetuximab (400 mg/m² on day -7 and then 250 mg/m² on days 0 and +8)
Study: 25680594
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) plus cetuximab
Study: 25682597
Drug: PR104 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR104 (dose ranged from 1.1 to 4 g/m(2))
Study: 25682597
Drug: PR104 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR104 (3 g/m(2) or 4 g/m(2))
Study: 25682597
Drug: PR104 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PR104 administration
Study: 25683846
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.2 mg/kg weekly on days 1, 8, and 15 for two 28-day cycles)
Study: 25683846
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (brentuximab vedotin followed by augICE)
Study: 25684279
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV) administered under medical supervision
Study: 25684479
Drug: Cancer survivors
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer survivors post cancer directed therapy (CDT)
Study: 25685352
Drug: Common Mental
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation and again 14 days later.
Study: 25685352
Drug: Common Mental
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation.
Study: 25687566
Drug: Cervicovaginal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervicovaginal fluid (CVF) IL-6 ≥463 pg/mL
Study: 25687566
Drug: 3-marker CVF
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-marker CVF model (IL-6 + CXCL1 + insulin-like growth factor binding protein-1)
Study: 25687867
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m(2) (day 1) and capecitabine 1,000 mg/m(2) twice a day (days 1 to 14) in 21-day cycles
Study: 25690834
Drug: Goal-Directed Fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-Directed Fluid Therapy (GDFT) using closed-loop fluid administration system with non-invasive cardiac output monitoring (Nexfin™)
Study: 25692692
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day)
Study: 25694653
Drug: LPV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r monotherapy (400/100 mg twice daily)
Study: 25694653
Drug: LPV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r monotherapy with FTC/TDF intensification as needed
Study: 25695490
Drug: Decursin (D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decursin (D) 119 mg
Study: 25695490
Drug: Decursinol angelate
Normalized name: Physalis angulata extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decursinol angelate (DA) 77 mg
Study: 25696062
Drug: Mean counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mean counts per minute of daily PA
Study: 25696062
Drug: Counts per
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counts per minute of daily PA (sex-specific)
Study: 25696919
Drug: Entospletinib (GS-9973)
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib (GS-9973) 800 mg twice daily
Study: 25698370
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week) for 52 weeks
Study: 25698370
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week)
Study: 25698370
Drug: Self-injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-injection of subcutaneous abatacept
Study: 25699246
Drug: Novel brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel brain and vestibular rehabilitation treatment for PTSD
Study: 25700037
Drug: Intracoronary cell
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary cell therapy
Study: 25700774
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and pemetrexed (DL1: 1250 mg/500 mg)
Study: 25700774
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and pemetrexed (DL0: 1250 mg/400 mg)
Study: 25700774
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and pemetrexed (DL2: 1500 mg/500 mg)
Study: 25700777
Drug: ≥5 CTC/7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥5 CTC/7.5 ml
Study: 25700777
Drug: Composite criteria
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite criteria (<5 CTC/7.5 ml or relative decrease ≥-70% of the baseline CTC count)
Study: 25701314
Drug: DTaP-HBV-IPV/Hib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-HBV-IPV/Hib combination vaccine
Study: 25704439
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) administered intravenously every 2 weeks until progression or unacceptable toxic effects
Study: 26187031
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks
Study: 25707037
Drug: Specific tweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific tweet content (setting quit date, use of nicotine patches)
Study: 25709506
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (GnRH antagonist initiated on day 10)
Study: 25709506
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (GnRH antagonist initiated on day 20)
Study: 25709506
Drug: Protocols B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocols B and C (GnRH antagonist protocols)
Study: 25710456
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of panobinostat (30 mg) and carfilzomib (20/45 mg/m²)
Study: 25710456
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of panobinostat and carfilzomib
Study: 25710659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INR reversal <1.3 within 4 hours and systolic BP <160 mm Hg at 4 hours
Study: 25710773
Drug: Sorbent Hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbent Hemodialysis (Allient system; Renal Solutions, Warrendale, PA)
Study: 25710812
Drug: Insulin therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin therapy, n=8
Study: 25711328
Drug: Neuropsychological tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropsychological tests administered (QNPZ-8 score)
Study: 25712364
Drug: Telaprevir monotherapy
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir monotherapy for 14 days followed by telaprevir-based triple therapy after 4.3 to 5.7 years
Study: 25712496
Drug: Breath holds
Normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath holds ending on either inhalation or exhalation
Study: 25712687
Drug: BI-505 (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI-505 (0.09 mg/kg or higher doses)
Study: 25712687
Drug: BI-505 (escalating
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI-505 (escalating doses from 0.0004 to 20 mg/kg)
Study: 25712687
Drug: BI-505 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI-505 (10 mg/kg doses)
Study: 25712687
Drug: BI-505 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI-505 (various doses)
Study: 25713585
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel (Crinone 8% gel) + intercourse
Study: 25713585
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel (Crinone 8% gel) + abstinence
Study: 25713600
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg (initially in RCT phase)
Study: 25713900
Drug: Urgent video
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urgent video capsule endoscopy (VCE)
Study: 25714828
Drug: Anticoagulants (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (vitamin K antagonists, factor Xa inhibitors, direct thrombin inhibitors)
Study: 25715311
Drug: Triple-Combination Cream
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-Combination Cream
Study: 25716221
Drug: Beta-blockers (bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (bisoprolol for at least 48 hours)
Study: 25716221
Drug: Beta-blockers (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (chronic group)
Study: 25716544
Drug: DEBIO1143 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEBIO1143 (oral administration, doses from 5 to 900 mg)
Study: 25716544
Drug: DEBIO1143 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEBIO1143 (oral administration, doses >80 mg)
Study: 25716544
Drug: DEBIO1143 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEBIO1143 (oral administration)
Study: 25719453
Drug: Darunavir/ritonavir 20/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 20/3 mg/kg twice-daily for 2 weeks, then adjusted to 25/3 mg/kg for patients <15 kg and 375/50 mg for patients 15 to <20 kg with an optimized background regimen (OBR)
Study: 25720077
Drug: Urinary Luteinising
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary Luteinising Hormone (LH)
Study: 25722272
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of serum anti-tissue transglutaminase antibodies during febrile illness
Study: 25726315
Drug: LES electrical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LES electrical stimulation therapy (LES-EST) at 20 Hz, 215 μs, 3-8 mAmp, delivered over 30-minute sessions, 6-12 sessions per day, starting on day 1 after implantation.
Study: 25726315
Drug: LES electrical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LES electrical stimulation therapy (LES-EST)
Study: 25728526
Drug: Alisertib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (50 mg twice daily for 7 days in 21-day cycles)
Study: 25728732
Drug: Mild CKD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild CKD (60-89 mL/min per 1.73 m²)
Study: 25730284
Drug: Esophageal video
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal video capsule endoscopy (ECE)
Study: 25730509
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy with raltegravir and Truvada during primary HIV infection (PHI)
Study: 25730509
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy with raltegravir and Truvada during chronic HIV infection (CHI)
Study: 25732635
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy based on ERCC1, RRM1, and TS protein expression
Study: 25732635
Drug: Non-individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-individualized treatment
Study: 25733005
Drug: Pevonedistat (MLN4924)
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A) at maximum tolerated dose (MTD) of 59 mg/m².
Study: 25733005
Drug: Pevonedistat (MLN4924)
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 4, 8 and 11 (schedule B) at maximum tolerated dose (MTD) of 83 mg/m².
Study: 25733630
Drug: Afebrile malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afebrile malaria treatment
Study: 25733630
Drug: S. haematobium
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. haematobium treatment
Study: 25734107
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) in TB patients
Study: 25734107
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) in non-TB patients
Study: 25734159
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (3.75 µg HA)
Study: 25734159
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine without AS03 adjuvant
Study: 25734159
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (7.5 µg HA)
Study: 25734159
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (15 µg HA)
Study: 25734254
Drug: Metreleptin (0.06-0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.06-0.24 mg/kg · d)
Study: 25739929
Drug: (2)H-α-tocopherol from
Normalized name: Tocopherols
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2)H-α-tocopherol from 120 g (2)H collard greens (1.2 ± 0.1 mg)
Study: 25740829
Drug: Belimumab therapy
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab therapy for 24 weeks
Study: 25740829
Drug: Belimumab therapy
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab therapy for 52 weeks
Study: 29336179
Drug: Belimumab therapy
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab therapy
Study: 25740857
Drug: Oral mucosal
Normalized name: Finafta Multi Oral Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mucosal disease (NIH Oral Mucosal Score, OMS)
Study: 25742165
Drug: mAb7F9 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb7F9 (200 mg/kg)
Study: 25742165
Drug: METH (0.1-0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: METH (0.1-0.56 mg/kg, s.c.)
Study: 25742165
Drug: METH (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: METH (0.3 mg/kg, s.c.)
Study: 25749662
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m² rapid intravenous infusion on days 1, 4, 8, and 11, followed by pegylated liposomal doxorubicin 30 mg/m² intravenous infusion on day 4, up to 6 cycles.
Study: 25751105
Drug: Activin A
Normalized name: Activin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activin A (ActA) concentrations in cachectic patients (CC)
Study: 25751105
Drug: Myostatin (Mstn)
Normalized name: nystatin Oral Suspension [Mycostatin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myostatin (Mstn) concentrations in cachectic patients (CC)
Study: 25752885
Drug: Integrative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative care (AIC) program with ≥ 4 CM treatments
Study: 25753361
Drug: Regorafenib at
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib at 160 mg/day, 3 weeks out of 4
Study: 25753604
Drug: Parenteral Amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Amino Acid Therapy (250 cc of AAs 3 times per week postdialysis for 8 weeks)
Study: 25755291
Drug: BR-ibrutinib (bendamustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR-ibrutinib (bendamustine and rituximab with ibrutinib 420 mg daily)
Study: 25755291
Drug: FCR-ibrutinib (fludarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCR-ibrutinib (fludarabine, cyclophosphamide, and rituximab with ibrutinib 420 mg daily)
Study: 25756303
Drug: CAPROS supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPROS supplementation (500 mg b.i.d for 12 weeks)
Study: 25757508
Drug: Platelet aggregation
Normalized name: Platelet aggregation inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet aggregation and secretion in response to exogenous agonists in patients with sepsis
Study: 25757607
Drug: Prolonged-release oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone/naloxone (PR OXN) for 12 weeks (median daily dose, 20 mg)
Study: 25757607
Drug: Prolonged-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone (PR OXY)
Study: 25758261
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) interruption
Study: 25758261
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) treatment
Study: 25758611
Drug: 1×dose (1.1×10(11)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1×dose (1.1×10(11) vg/hemisphere, unilateral or bilateral injection)
Study: 25758611
Drug: 5×dose (5.5×10(11)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5×dose (5.5×10(11) vg/hemisphere, bilateral injection)
Study: 25758611
Drug: 1×dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1×dose
Study: 25758746
Drug: Dasatinib with
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib with intrapatient dose escalation by 50 mg daily every cycle as tolerated
Study: 25760881
Drug: Microvascular angina
Normalized name: INVESTIGATIONAL ANTI-ANGINA DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microvascular angina diagnosis and treatment
Study: 25761109
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg) administered in up to four cycles at 3-week intervals
Study: 25762343
Drug: RG7356 (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7356 (humanized anti-CD44 antibody)
Study: 25762533
Drug: Atropine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (5 µg/kg) administered intravenously
Study: 25763783
Drug: TFV disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFV disoproxil fumarate/FTC therapy
Study: 25763866
Drug: N-Acetylcysteine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetylcysteine (150 mg/kg body weight)
Study: 25764096
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of blood in a single aerobic bottle
Study: 25764096
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL in aerobic and anaerobic bottles (control)
Study: 25764096
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL in a single aerobic bottle
Study: 25765333
Drug: Bumetanide 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 0.05 mg/kg
Study: 25765333
Drug: Bumetanide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 0.1 mg/kg
Study: 25765333
Drug: Bumetanide 0.2
Normalized name: bumetanide 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 0.2 mg/kg
Study: 25765333
Drug: Bumetanide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 0.3 mg/kg
Study: 25765333
Drug: Bumetanide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (all doses)
Study: 25766640
Drug: Anti-tumour necrosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumour necrosis factor (TNF) treatment
Study: 25768439
Drug: Pseudomonas aeruginosa-mannose-sensitive
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) 1 mg administered subcutaneously every other day and capecitabine 1000 mg/m2 orally twice a day for 2 weeks on, 1 week off.
Study: 25768671
Drug: Baseline copeptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline copeptin level >21.4 pmol/L
Study: 25768671
Drug: Stimulated copeptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulated copeptin >4.9 pmol/L (at sodium levels >147 mmol/L)